Efficacy of induction chemoradiotherapy with carboplatin and docetaxel for non-small cell lung cancer in stage III

Abstract

18510 Background: The aim of this study was to assess the usefulness of induction chemoradiotherapy with carboplatin and docetaxel for non-small cell lung cancer (NSCLC) in stage III. Methods: The clinicopathologic efficacy in 24 patients (a mean age of 62.7(56–80), 19 men and 5 female, 14 adenocarcinoma and 10 squamous cell carcinoma, clinical stage: 16 IIIA and 8 IIIB) with clinical N2 (diagnosed under 6 mediastinoscope, 2 thoracoscope, 7 FDG-PET, 1 CT guided biopsy, and 1 TBNA) or T4 (invasion to vertebra body) who received induction therapy from April 2001 through October 2007 were evaluated. The patients who evaluated as SD or PR or CR after induction chemotherapy [2 cycles of carboplatin (AUC 6)+docetaxel (60 mg/m2) every monthly or 4 cycles of carboplatin (AUC 3)+docetaxel (30 mg/m2) every biweekly] with concurrent thoracic radiotherapy (TD 40 Gy/20 fr.), underwent surgical lung resection. Results: Total response rate of induction therapy was 83%, including down stage rate in 50%, surgical resection rate in 96% and complete resection rate in 69%. Pathologic effect was EF 1 in 9, EF 2 in 8 and EF 3 in 6. Median survival was 10.9 months in EF1 and 25 months in EF2. All EF 3 patients still alive with a mean survival of 60 months (32–76 months). From the point of survival time, there was a significant difference between EF 3 and EF 1 (p<0.05), but there was no significant difference in age, gender, PS, pathologic type, clinical stage and complete or incomplete resection. Conclusions: Pathologic effect was correlated with prognosis after induction therapy in stage III NSCLC. No significant financial relationships to disclose.